Published in Clin Transpl on January 01, 1999
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science (1997) 11.89
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
Kidney transplantation under FK 506. JAMA (1990) 7.45
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation (1973) 6.01
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity (1998) 5.38
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature (1993) 4.26
Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science (1999) 4.20
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Gene regulation mediated by calcium signals in T lymphocytes. Nat Immunol (2001) 4.09
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Partners in transcription: NFAT and AP-1. Oncogene (2001) 3.83
Prevalence of Alzheimer's disease and other dementias in rural India: the Indo-US study. Neurology (1998) 3.82
Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA. Nature (1998) 3.71
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Crystallographic structure of the nitrogenase iron protein from Azotobacter vinelandii. Science (1992) 3.58
Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49
Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell (2000) 3.44
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity (2001) 3.43
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Nuclear factor of activated T cells contains Fos and Jun. Nature (1992) 3.43
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Consensus statement on the live organ donor. JAMA (2000) 3.29
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Transcriptional regulation of the IL-2 gene. Curr Opin Immunol (1995) 3.14
GKAP, a novel synaptic protein that interacts with the guanylate kinase-like domain of the PSD-95/SAP90 family of channel clustering molecules. J Cell Biol (1997) 2.92
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J Immunol (2001) 2.85
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J Virol (2001) 2.76
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
An enhanced immune response in mice lacking the transcription factor NFAT1. Science (1996) 2.55
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. Proc Natl Acad Sci U S A (1999) 2.48
Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT. Mol Cell (1998) 2.44
Competitive binding of alpha-actinin and calmodulin to the NMDA receptor. Nature (1997) 2.41
Maternal feeding practices and beliefs and their relationships to overweight in early childhood. J Dev Behav Pediatr (2001) 2.39
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Characterization of influenza virus RNA complete transcripts. Virology (1982) 2.31
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol (1999) 2.28
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci U S A (1995) 2.24
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res (2001) 2.22
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22
Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet (2000) 2.21
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J (2002) 2.19
Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther (2001) 2.19